Picture loading failed.

Pre-Made Elipovimab biosimilar, Whole Mab: Anti-HIV-1 gp120 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Elipovimab (formerly known as GS-9722) is a first in class of effector-enhanced broadly neutralizing HIV-1 antibodies for the targeted elimination of HIV infected cells and is as of 2020 in phase 1b clinical testing, designed with the goal of reducing or eliminating the HIV reservoir in patients.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-171-1mg 1mg 3090
GMP-Bios-ab-171-10mg 10mg 21890
GMP-Bios-ab-171-100mg 100mg 148000
GMP-Bios-ab-171-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Elipovimab biosimilar, Whole Mab: Anti-HIV-1 gp120 therapeutic antibody
INN Name Elipovimab
TargetHIV-1 gp120
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI Structure4fq1:HL/4jy4:BA/4fqc:HL
Year Proposed2018
Year Recommended2019
CompaniesGilead Sciences
Conditions Approvedna
Conditions ActiveHIV infections
Conditions Discontinuedna
Development Techna